Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
- Written by PR Newswire
.. First ovarian cancer therapy for ST oncology portfolio
.. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone 1
.. Phase 3 results expected in 2025
.. Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam
SINGAPORE and SEOUL,...